Evidence map›Paper›PMID 39171829›Full record

Trial reportBrain : a journal of neurology2024

Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study.

Andrea Calcagno, Jessica Cusato, Paola Cinque, Giulia Marchetti, Davide Bernasconi, Mattia Trunfio, Elena Bruzzesi, Stefano Rusconi, Arianna Gabrieli, Antonio Muscatello and 5 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Brain : a journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Epigenetic mechanisms of HIV and opioid-induced neuropathology: Potential therapies and interventions.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  4. Article
  5. Update on neurological complications of HIV.Current opinion in HIV and AIDS · 2025
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Andrea CalcagnoUnit of Infectious Diseases, Department of Medical Sciences, University of Turin, 10149 Turin, Italy.ORCID 0000-0003-2534-8815
Jessica CusatoLaboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, 10149 Turin, Italy.ORCID 0000-0003-1977-9694
Paola CinqueInfectious Diseases Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
Giulia MarchettiClinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.
Davide BernasconiBicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Mattia TrunfioUnit of Infectious Diseases, Department of Medical Sciences, University of Turin, 10149 Turin, Italy.ORCID 0000-0001-8663-719X
Elena BruzzesiInfectious Diseases Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
Stefano RusconiSchool of Medicine and Surgery, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-0375-9990
Arianna GabrieliDipartimento di Scienze Biomediche e Cliniche (DIBIC), 20157 Milan, Italy.
Antonio MuscatelloInfectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Andrea AntinoriClinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.
Diego RipamontiInfectious Disease Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.ORCID 0000-0001-6702-6668
Roberto GulminettiDivision of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
Miriam AntonucciSCDU Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, 10149 Turin, Italy.
Silvia NozzaInfectious Diseases Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.ORCID 0000-0002-2673-2731

Funding

Italian Ministry of HealthRicerca Finalizzata di Rete NET-2013-02355333Viiv Healthcare
6 · The paper itself

Abstract

It is debated whether CNS involvement begins during acute human immunodeficiency virus (HIV) infection in persons without meningitis/encephalitis and whether specific antiretroviral drugs or combinations would be beneficial. Neurologically asymptomatic participants enrolled in a randomized and controlled study comparing three combination antiretroviral regimens (tenofovir alafenamide/emtricitabine plus dolutegravir; darunavir; or both) during primary HIV infection were enrolled. Serum and CSF were collected at baseline and at 12 and 48 (serum only) weeks after treatment initiation. Single molecule array was used to measure neurofilament light chain (NFL), total tau protein (Tau), brain-derived neurotrophic factor, glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase. We assessed the longitudinal change in biomarkers over time, in addition to the change in the prevalence of serum NFL concentrations above previously published age-adjusted cut-offs (7 pg/ml if 5-18 years, 10 pg/ml if 18-51 years, 15 pg/ml if 51-61 years, 20 pg/ml if 61-70 years and 35 pg/ml if >70 years). Serum was available from 47 participants at all time points, and CSF was available from 13 participants at baseline and 7 at Week 12. We observed a significant direct serum-to-CSF correlation for NFL (ρ = 0.692, P = 0.009), GFAP (ρ = 0.659, P = 0.014) and brain-derived neurotrophic factor (ρ = 0.587, P = 0.045). Serum (ρ = 0.560, P = 0.046) and CSF NFL (ρ = 0.582, P = 0.037) concentrations were directly associated with CSF HIV RNA levels. We observed a significant decrease over time in serum NFL (P = 0.006) and GFAP (P = 0.006) but not in the other biomarkers. No significant difference was observed among the treatment arms. At baseline, serum and CSF age-adjusted NFL levels were above age-adjusted cut-offs in 23 (48.9%) and four participants (30.8%), respectively; considering serum NFL, this proportion was lower at Weeks 12 (31.9%, P = 0.057) and 48 (27.7%, P = 0.13). A relevant proportion of neurologically asymptomatic participants had abnormal CSF and serum NFL levels during primary HIV infection. NFL and GFAP decreased in serum following combination antiretroviral therapy without significant differences among the treatment arms.

Indexed as

BiomarkersHIV InfectionsNeurofilament ProteinsAdolescentAdultAgedBrain-Derived Neurotrophic FactorDarunavirDolutegravirEmtricitabineFemaleGlial Fibrillary Acidic ProteinHeterocyclic Compounds, 3-RingHumansMaleMiddle AgedBiomarkersBrain-Derived Neurotrophic FactorDarunavirDolutegravirEmtricitabineGFAP protein, humanGlial Fibrillary Acidic ProteinHeterocyclic Compounds, 3-Ringneurofilament protein LNeurofilament ProteinsOxazinesPiperazinesPyridonestau ProteinsTenofovirantiretroviral therapycerebrospinal fluidglial fibrillary acidic proteinneurofilament light chainneurological injury

Identifiers

PMID39171829
PMCPMC11907231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.